Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 10/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | CALML3 | P27482 | 1/20 | 0.44 |
| ▸ | SDHA | P31040 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800217 | 1.00 | GRM2 (0.53) | GRM2RORCF10MAOAMAOB | |
| SCHEMBL2799650 | 0.84 | MAOA (0.53) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL2799645 | 0.84 | MAOA (0.53) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL14197146 | 0.82 | MAOB (0.46) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL9550280 | 0.82 | GRM2 (0.56) | GRM2F10MAOAMAOBLMNA | |
| SCHEMBL20802077 | 0.82 | F10 (0.54) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL1224396 | 0.81 | MAOA (0.58) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL1224398 | 0.81 | MAOA (0.58) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL18779796 | 0.81 | F10 (0.65) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL14314011 | 0.81 | F10 (0.65) | F10MAOAMAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288423-B2 | FXa inhibitors with cyclic amidines as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof | LEGOCHEM BIOSCIENCE LTD. (KR) | 2012-10-16 | — | — | US | disclosed |
| US-20100184781-A1 | FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | LEGOCHEM BIOSCIENCE LTD. (KR) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184781-A1 | FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | F12, F2, TFPI | GRM2 4803/4885RORC 4439/4885F10 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.